Adaptimmune Therapeutics Plc (ADAP) — Cash Flow Quality Index

Latest as of June 2024: 0.68x

Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow Quality Index of 0.68x as of June 2024. Operating cash flow of $47.39 Million is below net income of $69.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Adaptimmune Therapeutics Plc total assets for the complete picture of this company's asset base.

Cash Flow Quality Index

0.68x

Operating CF / Net Income

Operating Cash Flow

$47.39 Million

USD

Net Income

$69.52 Million

USD

Data as of

Jun 2024

Most recent filing

Annual Cash Flow Quality Index for Adaptimmune Therapeutics Plc (None–None)

Year-by-year earnings quality comparison for Adaptimmune Therapeutics Plc. For live market cap and the full company financial profile, see ADAP stock market capitalisation.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.